
    
      It is a prospective randomized phase III clinical trial sponsored by Shanghai Zhongshan
      Hospital with other eight hospitals in China participating in. 264 patients with locally
      advanced resectable esophageal squamous cell carcinoma(cT3-4aN0-1M0) are recruited and
      randomly assigned into the neoadjuvant chemoradiotherapy group (NCRT group) and the
      neoadjuvant chemotherapy group (NCT group) according to the proportion of 1:1.The
      safety,efficacy of protocols and prognosis of patients are compared between the two regimens.
    
  